KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Operating Expenses (2016 - 2025)

Novavax (NVAX) has 16 years of Operating Expenses data on record, last reported at $132.9 million in Q4 2025.

  • For Q4 2025, Operating Expenses fell 39.42% year-over-year to $132.9 million; the TTM value through Dec 2025 reached $670.7 million, down 27.97%, while the annual FY2025 figure was $670.7 million, 27.97% down from the prior year.
  • Operating Expenses reached $132.9 million in Q4 2025 per NVAX's latest filing, down from $248.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $1.0 billion in Q4 2021 and bottomed at $132.9 million in Q4 2025.
  • Average Operating Expenses over 5 years is $430.6 million, with a median of $381.3 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: surged 2396.24% in 2021, then tumbled 63.72% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $1.0 billion in 2021, then tumbled by 42.58% to $601.3 million in 2022, then dropped by 21.02% to $474.9 million in 2023, then tumbled by 53.8% to $219.4 million in 2024, then crashed by 39.42% to $132.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $132.9 million in Q4 2025, $248.5 million in Q3 2025, and $138.2 million in Q2 2025.